Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q3

4587.TEDINET S100PLL7
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
MetricValuePeriodScopeSource row
Revenue¥11.2bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.2bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥7.8bn2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥4.9bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income−¥427m2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.2bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥4.0bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥3.6bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax−¥369m2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.8bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥3.5bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥187m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥946m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥187m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥946m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥51.3bnat 2022-09-30Cons.Assets IFRS
Total assets¥27.0bnat 2021-12-31Cons.Assets IFRS
Total assets¥28.1bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Assets IFRS
Total liabilities¥26.8bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥1.7bnat 2021-12-31Cons.Liabilities IFRS
Total liabilities¥4.9bnat 2020-12-31dCons.Liabilities IFRS
Net assets / equity¥24.5bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥25.2bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥21.3bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥24.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.2bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS
Cash & equivalents¥4.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.2bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥6.6bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥27.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.7bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥20.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥66m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥45m2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-1.442022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.282022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥19.962021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥19.252021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.132021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-1.442022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.062021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.122021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio47.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio89.4%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 13
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥8m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥197m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥8m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥183m
—segment totalrevenue2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥8m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥14m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 629
ItemContextValueUnit
Borrowings ncl IFRSPrior2YearInstant－JPY
Borrowings ncl IFRSPrior1YearInstant－JPY
Borrowings ncl IFRSCurrentQuarterInstant18905874000JPY
Other financial liabilities ncl IFRSPrior2YearInstant－JPY
Other financial liabilities ncl IFRSPrior1YearInstant－JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant383173000JPY
Deferred tax liabilities IFRSPrior2YearInstant－JPY
Deferred tax liabilities IFRSPrior1YearInstant308298000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant893024000JPY
Retirement benefit liability ncl IFRSPrior2YearInstant－JPY
Retirement benefit liability ncl IFRSPrior1YearInstant－JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant144305000JPY
Non current labilities IFRSPrior2YearInstant－JPY
Non current labilities IFRSPrior1YearInstant308298000JPY
Non current labilities IFRSCurrentQuarterInstant20326378000JPY
Liabilities IFRSPrior2YearInstant4862168000JPY
Liabilities IFRSPrior1YearInstant1684345000JPY
Liabilities IFRSCurrentQuarterInstant26785037000JPY
Share capital IFRSPrior2YearInstant3933885000JPY
Share capital IFRSPrior1YearInstant3956738000JPY
Share capital IFRSCurrentQuarterInstant3956738000JPY
Capital surplus IFRSPrior2YearInstant10305306000JPY
Capital surplus IFRSPrior1YearInstant4452358000JPY
Capital surplus IFRSCurrentQuarterInstant4457861000JPY
Treasury shares IFRSPrior2YearInstant-655383000JPY
Treasury shares IFRSPrior1YearInstant-620123000JPY
Treasury shares IFRSCurrentQuarterInstant-607255000JPY
Retained earnings IFRSPrior2YearInstant7503531000JPY
Retained earnings IFRSPrior1YearInstant16372687000JPY
Retained earnings IFRSCurrentQuarterInstant16186083000JPY
Other components of equity IFRSPrior2YearInstant191468000JPY
Other components of equity IFRSPrior1YearInstant1188589000JPY
Other components of equity IFRSCurrentQuarterInstant479149000JPY
Equity attributable to owners of parent IFRSPrior2YearInstant21278808000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant25350250000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant24472577000JPY
Equity IFRSPrior2YearInstant21278808000JPY
Equity IFRSPrior1YearInstant25350250000JPY
Equity IFRSCurrentQuarterInstant24472577000JPY
Liabilities and equity IFRSPrior2YearInstant26140976000JPY
Liabilities and equity IFRSPrior1YearInstant27034596000JPY
Liabilities and equity IFRSCurrentQuarterInstant51257614000JPY
Revenue IFRSPrior1YTDDuration7819342000JPY
Revenue IFRSCurrentYTDDuration11208540000JPY
Cost of sales IFRSPrior1YTDDuration1684354000JPY
Cost of sales IFRSCurrentYTDDuration5686909000JPY
Gross profit IFRSPrior1YTDDuration6134987000JPY
Gross profit IFRSCurrentYTDDuration5521631000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration1045528000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration4056806000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2020-12-31pass
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass